Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

被引：28

作者：

Beg, Muhammad Shaalan ^{[1
,2
]}

Huang, Xiumei ^{[2
,3
,4
]}

Silvers, Molly A. ^{[2
]}

Gerber, David E. ^{[1
,2
]}

Bolluyt, Joyce ^{[2
]}

Sarode, Venetia ^{[2
,5
]}

Fattah, Farjana ^{[2
]}

Deberardinis, Ralph J. ^{[3
,4
,6
]}

Merritt, Matthew E. ^{[7
]}

Xie, Xian-Jin ^{[2
]}

Leff, Richard ^{[8
]}

Laheru, Daniel ^{[9
]}

Boothman, David A. ^{[2
,3
,4
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Hematol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Harold Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX USA

[4] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA

[6] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA

[7] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA

[8] Texas Tech Univ, Hlth Sci Ctr, Clin Pharmacol & Expt Therapeut Ctr, Sch Pharm, Dallas, TX USA

[9] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2017年 / 116卷 / 01期

关键词：

beta-lapachone; cancer metabolism; experimental therapeutics; hyperpolarization; pancreatic cancer; CHIMERIC-ANTIGEN-RECEPTOR; STEM-CELL ANTIGEN; CAR-T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; MESOTHELIN-RELATED PROTEIN; ANTITUMOR-ACTIVITY; B-CELL; CARCINOEMBRYONIC ANTIGEN; PHYSICAL BARRIERS; MOUSE MODEL;

D O I：

10.1002/jso.24624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered compared to levels in associated normal pancreas tissue. ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H2O2) levels; normal tissues are spared by low NQO1 and high catalase expression. DNA damage created by ARQ761 in pancreatic cancer cells "hyperactivates" PARP1, causing metabolic catastrophe and NAD +/- keresis cell death. NQO1: catalase levels (high in tumor, low in normal tissue) are an attractive therapeutic window to treat pancreatic cancer. Based on a growing body of literature, we are leading a clinical trial to evaluate the combination of ARQ761 and chemotherapy in patients with pancreatic cancer.

引用

页码：83 / 88

页数：6

共 145 条

[1] A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer [J].

Abate-Daga, Daniel ;

Lagisetty, Kiran H. ;

Tran, Eric ;

Zheng, Zhili ;

Gattinoni, Luca ;

Yu, Zhiya ;

Burns, William R. ;

Miermont, Anne M. ;

Teper, Yaroslav ;

Rudloff, Udo ;

Restifo, Nicholas P. ;

Feldman, Steven A. ;

Rosenberg, Steven A. ;

Morgan, Richard A. .

HUMAN GENE THERAPY, 2014, 25 (12) :1003-1012

[2] Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].

Adusumilli, Prasad S. ;

Cherkassky, Leonid ;

Villena-Vargas, Jonathan ;

Colovos, Christos ;

Servais, Elliot ;

Plotkin, Jason ;

Jones, David R. ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)

[3] Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer [J].

Aida, Kouichirou ;

Miyakawa, Reina ;

Suzuki, Koji ;

Narumi, Kenta ;

Udagawa, Takeshi ;

Yamamoto, Yuki ;

Chikaraishi, Tatsuya ;

Yoshida, Teruhiko ;

Aoki, Kazunori .

CANCER SCIENCE, 2014, 105 (02) :159-167

[4] IMMUNOHISTOCHEMISTRY OF CEA IN THE HUMAN-PANCREAS DURING DEVELOPMENT, IN THE ADULT, CHRONIC-PANCREATITIS, AND PANCREATIC ADENOCARCINOMA [J].

ALBERS, GHR ;

FLEUREN, G ;

ESCRIBANO, MJ ;

NAP, M .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1988, 90 (01) :17-22

[5] DEMONSTRATION OF CARCINOEMBRYONIC ANTIGEN (CEA) EXPRESSION IN NORMAL, CHRONICALLY INFLAMED, AND MALIGNANT PANCREATIC TISSUE BY IMMUNOHISTOCHEMISTRY [J].

ALLUM, WH ;

STOKES, HJ ;

MACDONALD, F ;

FIELDING, JWL .

JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (06) :610-614

[6] Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis [J].

Amin, S. ;

Mhango, G. ;

Lin, J. ;

Aronson, A. ;

Wisnivesky, J. ;

Boffetta, P. ;

Lucas, Aimee L. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (09) :1350-1357

[7]

Argani P, 2001, CANCER RES, V61, P4320

[8] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].

Beatty, Gregory L. ;

Haas, Andrew R. ;

Maus, Marcela V. ;

Torigian, Drew A. ;

Soulen, Michael C. ;

Plesa, Gabriela ;

Chew, Anne ;

Zhao, Yangbing ;

Levine, Bruce L. ;

Albelda, Steven M. ;

Kalos, Michael ;

June, Carl H. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120

[9] Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3 [J].

Bharadwaj, Uddalak ;

Li, Min ;

Chen, Changyi ;

Yao, Qizhi .

MOLECULAR CANCER RESEARCH, 2008, 6 (11) :1755-1765

[10] The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].

Bingle, L ;

Brown, NJ ;

Lewis, CE .

JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265

← 1 2 3 4 5 6 7 8 9 10 →